Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of mismatch repair-deficient/microsatellite instability-high advanced or recurrent endometrial cancer, in India. Zejula is the only PARP inhibitor approved as first-line monotherapy maintenance for all biomarket types in advanced ovarian cancer in India, the company said.
